Koliko dividende plaća Recordati Industria Chimica e Farmaceutica SpA 2024?
Na dan decembar 2024, Recordati Industria Chimica e Farmaceutica SpA je u poslednjih 12 meseci isplatio ukupnu dividendu od 1,17 EUR po akciji. Pri trenutnoj Recordati Industria Chimica e Farmaceutica SpA ceni od 50,90 EUR, to odgovara dividendnom prinosu od 2,30 %.
Dividenda se isplaćuje 2 puta godišnje.
2,30 % Дивидендни принос | = | 1,17 EUR Dividenda | 50,90 EUR Cena akcije |
|
Da li je Recordati Industria Chimica e Farmaceutica SpA dividenda sigurna?
Recordati Industria Chimica e Farmaceutica SpA povećava dividendu već 11 godina.
U poslednjih 10 godina, Recordati Industria Chimica e Farmaceutica SpA je ovo povećao/la za 13,842 % godišnje povećana.
Na petogodišnjem nivou porastao isplata je povećana za 5,862 %.
Analitičari očekuju za tekuću poslovnu godinu rast od Povećanje dividendi% na 3,432%.
Recordati Industria Chimica e Farmaceutica SpA Aktienanalyse
Шта ради Recordati Industria Chimica e Farmaceutica SpA?
Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide.
Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology.
Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions.
Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia).
Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative.
In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers.
In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas. Recordati Industria Chimica e Farmaceutica SpA je jedna od najpopularnijih kompanija na Eulerpool.com.Plansovi za štednju u akcijama nude atraktivnu mogućnost za investitore da dugoročno izgrade bogatstvo. Jedna od glavnih prednosti je takozvani efekat prosečne cene: investiranjem redovnog fiksnog iznosa u akcije ili fondove akcija, automatski se kupuju više deonica kada su cene niske i manje kada su visoke. To može dovesti do povoljnijeg prosečnog cena po deonici tokom vremena. Pored toga, plansovi za štednju u akcijama omogućuju čak i malim ulagačima pristup skupim akcijama, pošto je moguće učestvovati već sa malim iznosima. Redovno investiranje takođe podstiče disciplinovanu strategiju ulaganja i pomaže da se izbegnu emocionalne odluke, kao što su impulsivno kupovanje ili prodaja. Osim toga, investitori profitiraju od potencijalnog povećanja vrednosti akcija kao i od isplata dividendi, koje se mogu reinvestirati, što pojačava efekat kamate na kamatu i time rast investiranog kapitala.